Bayer Completes Acquisition of China’s Dihon Pharmaceutical
Bayer has completed the acquisition of 100 percent of the shares of Dihon Pharmaceutical Group Co., Ltd., Kunming, Yunnan, China, a privately held pharmaceutical company specializing primarily in over-the-counter (OTC) dermatology products and herbal traditional Chinese medicine (TCM) products for various women's health indications. Bayer paid a purchase price of CNY 3.6 billion (EUR 460 million or $578 million).
Dihon generated sales of EUR 123 million ($154 million) in 2013. The company employs approximately 2,400 people in R&D, manufacturing, sales, and marketing. In addition to operations in China, Dihon brands are sold in other countries such as Nigeria, Vietnam, Myanmar, and Cambodia. Dihon's headquarters is located in Kunming, China. The company also has several manufacturing sites throughout China.
Source: Bayer HealthCare